NCT03549559 Imaging Histone Deacetylase in the Heart
| NCT ID | NCT03549559 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Heart Failure With Normal Ejection Fraction |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2018-09-07 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2018-09-07 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.
Eligibility Criteria
Inclusion Criteria: Group 1: Healthy Volunteers (n = 30) * Healthy adults with no known history of medical disease * Age 18-85 years * No history cardiovascular disease * Ability to provide informed consent Group 2: Patients with Diabetes (n = 16) * Age 18-85 years * Diagnosis of diabetes * Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction * Ability to provide informed consent Group 3: Patients with Aortic Stenosis (n = 50) * Age 18-85 years * Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis * Ability to provide informed consent Exclusion Criteria: * Known contraindication to MRI
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03549559 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Heart Failure With Normal Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03549559 currently recruiting?
Yes, NCT03549559 is actively recruiting participants. Contact the research team at dsosnovik@mgh.harvard.edu for enrollment information.
Where is the NCT03549559 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT03549559 clinical trial?
NCT03549559 is sponsored by Massachusetts General Hospital. The trial plans to enroll 96 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.